NEW YORK & SHANGHAI -- (BUSINESS WIRE) --
HD Biosciences Co., Ltd. (HDB), a Shanghai-based biotechnology company specializing in high value drug discovery contract research services, and Pfizer Inc announced today that Pfizer awarded HD Biosciences its “2008 Top Research Service Partner Award” in recognition of quality, productivity, and value that HD Biosciences brought to Pfizer over the past year.
“We are thrilled by this recognition from Pfizer,” said Dr. Xuehai Tan. “HDB is honored to be an elite partner in Pfizer’s global collaborative research network. The award reflects the commitment from both sides at the very beginning of the collaboration to build a long-term productive and rewarding relationship. HDB will continue to invest the necessary resources to build HDB into a comprehensive, biology-centric contract research operation that meets the growing demand of Pfizer research as well as our other clients.”
The award was presented to Dr. Xuahai Tan, President and CEO of HDB by Richard Connell, PhD, VP and Head of the External Research Solutions Center of Excellence in Pfizer. HD Biosciences has been collaborating with multiple Pfizer research sites including Groton, La Jolla, USA, and Sandwich, UK, to provide top quality biology discovery services ranging from assay development and validation, to plate based screening in both cell-based and biochemical assay formats.
“Pfizer recognized early on the potential of HDB as both a quality service provider and an emerging player in the R&D service space. This was a key driver in the decision to make an equity investment in HDB earlier this year,” said Steve Yang, VP, Head of R&D, Asia, Pfizer.
As one of the largest biology-focused CROs in China, HDB collaborates with Pfizer in many research areas. High quality deliverables, fast turnaround time, and excellent communication and professionalism earned HDB great appreciation and praise from many research teams within Pfizer. “HDB has provided us tremendous plate-based biology and integrated program screening flexibility in 2008,” said Pfizer’s’ Rick Connell.
About HD Biosciences Co., Ltd.
HD Biosciences Co., Ltd. is a biotechnology company based in Shanghai, China, that specializes in high value drug discovery contract research services. With operation units in Shanghai and Beijing, China, HD Biosciences has experienced and dedicated teams to meet the R&D needs of pharmaceutical and biotechnology companies all over the world. HDB offers a broad range of services in a high-throughput setting for plate-based pharmacology and compound profiling, including but not limited to GPCR, ion channel, kinase profiling, and is expanding to in vitro/in vivo DMPK and animal disease models research areas.
About Pfizer Inc: Working together for a healthier world™
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support. At Pfizer, colleagues in more than 90 countries work every day to help people stay happier and healthier longer and to reduce the human and economic burden of disease worldwide.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5902647⟨=en
CONTACT:
HD Biosciences Contact:
Angela Chen, 86-21-58558330 *102
angelachen@hdbiosciences.com
OR
Pfizer Contacts:
Shreya Jani (U.S.), 212-733-4889
Shreya.jani@pfizer.com
OR
Julien Dedman (Asia), +852-2287-9985
Julien.dedman@pfizer.com